利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

4506 records (took 0.038 seconds)

    COMPOSITIONS COMPRISING A CANNABINOID AND SPILANTHOL
    62.
    发明申请
    COMPOSITIONS COMPRISING A CANNABINOID AND SPILANTHOL 有权

    公开(公告)号：US20210177800A1

    公开(公告)日：2021-06-17

    申请号：US17188023

    申请日：2021-03-01

    Applicant: SciCann Therapeutics Inc.

    Inventor： Zohar KOREN

    IPC: A61K31/352 ,  A61P1/16 ,  A61K31/16

    Abstract: Provided herein are fixed-dose combination (FDC) compositions comprising therapeutically effective amounts of at least one cannabinoid and spilanthol whether as essentially pure isolates or synthetics or as components of essential oils or plant extracts or combinations thereof. The compositions are formulated as pharmaceutical compositions, nutraceuticals, cosmeceuticals, nutricosmetics, cosmetics, or food products. The pharmaceutical compositions are useful for the treatment of a gastro-enteric disease selected from the group consisting of irritable bowel disease, Crohn's disease, colitis, irritable bowel syndrome, and acute and chronic pancreatitis or of sepsis. Other pharmaceutical uses are as anti-allergic, anti-inflammatory, immunomodulator, antioxidant, anti-microbial, antibacterial, antifungal, antiviral, antinociceptive, analgesic, anesthetic, anti-cancer, apoptosis inducing, antiscorbutic, antipyretic, anti-malarial, addiction mitigatory, anxiolytic, anti-depressant, diuretic, anti-diarrheal, vasodilator or aphrodisiac agents. The pharmaceutical compositions of this invention exhibit a synergistic effect.

    METHODS FOR TARGETING PAIN DIRECTED AT METABOLIC PATHWAYS
    63.
    发明申请
    METHODS FOR TARGETING PAIN DIRECTED AT METABOLIC PATHWAYS 有权

    公开(公告)号：US20210161944A1

    公开(公告)日：2021-06-03

    申请号：US17258544

    申请日：2019-08-14

    Applicant: Ohannes Kevork MELEMEDJIAN

    Inventor： Ohannes Kevork MELEMEDJIAN

    IPC: A61K31/7105 ,  A61K31/19 ,  A61K31/16 ,  A61K31/7004 ,  A61K47/54 ,  C12N15/113

    Abstract: Methods of alleviating or prophylactically blocking pain through the alteration of certain metabolic pathways in a subject experiencing pain or expecting to experience pain are disclosed. In particular, methods of increasing the amount of the neutral amino acid transporter ASCT2 in neurons are disclosed. Increased glutamine uptake by neurons leads to reduced extrusion of lactate and protons into the extracellular space and by extension, reduced sensitization of the neurons. Reduced sensitization of the neurons lessens the feeling of pain in the subject.

    Envenomation therapies and related pharmaceutical compositions, systems and kits
    64.
    发明授权
    Envenomation therapies and related pharmaceutical compositions, systems and kits 有权

    公开(公告)号：US11000506B2

    公开(公告)日：2021-05-11

    申请号：US15528418

    申请日：2015-11-20

    Applicant: OPHIREX, INC

    Inventor： Matthew R. Lewin

    IPC: A61K31/404 ,  A61K31/167 ,  A61K31/445 ,  A61K31/381 ,  A61K31/541 ,  A61K31/405 ,  A61K31/24 ,  A61K31/245 ,  A61K31/16 ,  A61K38/57 ,  A61K9/00 ,  A61K45/06 ,  A61K39/395 ,  C07K16/18

    Abstract: The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and/or adjunct therapy with antivenom using at least one active component, in some instances at least two active components and in other instances no more than two active components selected from the group consisting of a selective secretory PLA2 inhibitor (sPLA2 or PLA2 inhibitor), a metalloproteinase inhibitor, a serine protease inhibitor, antivenom, one or more acetylcholinesterase inhibitors or a nAChR agonist paired with a mAChR antagonist, a NMDA receptor antagonist and a spreading factor inhibitor to treat a subject who suffers from an envenomation, preferably at the time of envenomation and often within a period of less than about an hour after an envenomation or 6 hours after an envenomation and throughout the course of treatment at time with or without antivenom as an adjunct therapy after an envenomation by, for example, a snake or invertebrate.

    Method of improvement of insulin sensitivity in obese patients
    68.
    发明授权
    Method of improvement of insulin sensitivity in obese patients 有权

    公开(公告)号：US10888536B1

    公开(公告)日：2021-01-12

    申请号：US16553822

    申请日：2019-08-28

    Applicant: FOOYIN UNIVERSITY

    Inventor： Ming-Hsiu Wu

    IPC: A61K31/16 ,  A61K31/164 ,  A61P3/10 ,  A61K9/00

    Abstract: A method for improving insulin sensitivity in obesity-induced metabolic syndrome by administering propanamide to a subject in need thereof the increase of ATP synthesis, decreasing inflammation, reducing accumulation of visceral fat and improving hyperglycemia and hyperinsulinemia. Propanamide can be orally administered to the subject. Propanamide can be administered to the subject in a dosage of 11.56-15.38 mg/kg/day. Propanamide can be administered to the subject postprandially.

Patent Agency Ranking